AOL Money & Finance

consumer products posts

Feed

Clorox starts its new year off right

Clorox (NYSE: CLX), a consumer-products business that counts Procter & Gamble (NYSE: PG) and Colgate-Palmolive (NYSE: CL) as related stocks, may have seen a sales drop of 1% in its fiscal first quarter, but that didn't stop it from posting a nice bottom-line growth rate. Clorox made $1.11 per share in Q1, and that represents a 23% increase. What a way to start a new corporate year!

According to Reuters, expectations were for 95 cents per share. That's a wonderful beat. Plus, sales volume went up 1%. Helping to drive things along was a healthy gross margin, as well as the dreaded H1N1 virus. Clorox has done well over the years associating its brand with sanitizing effectiveness, so when a pandemic rears its ugly head, the trademark is prepared to leverage such reputation to drive value.

Continue reading Clorox starts its new year off right

Avon sold on Q3 news, but think long term

Avon Products (NYSE: AVP) had a difficult third quarter. Currency translations helped to drive a 4% decrease in net revenue. Excluding that effect, sales were up 7%. Net income decreased a big 31% to 36 cents per share.

However, according to Reuters, adjusted earnings of 42 cents per share beat analyst projections by two pennies. Such news didn't seem to matter to the market. At the time of this writing, Avon was down 1.9% on significant volume.

Continue reading Avon sold on Q3 news, but think long term

Kimberly-Clark high on Q3 data

Kimberly-Clark Corporation (NYSE: KMB), a consumer products entity whose colleagues include Procter & Gamble (NYSE: PG) and Johnson & Johnson (NYSE: JNJ), is up today on third-quarter results. At the time of this writing, my screen was showing shares of Kimberly-Clark higher by a little under 6%.

According to the corporate press release, sales declined 1.7%. Not a great start, but Kimberly-Clark highlighted a better metric: organic sales increased 3%, helped along by price increases. Luckily, sales volume didn't fare too badly; they were essentially flat.

Continue reading Kimberly-Clark high on Q3 data

Del Monte up big on Q1 data

Del Monte Foods (NYSE: DLM), a supermarket brand whose colleagues include ConAgra (NYSE: CAG) and Kraft (NYSE: KFT), was way up in afternoon trading. When a stock like Del Monte gains 9% on great volume, you know something big must have happened. Well, it was the company's fiscal Q1 results that made investors want to buy today. After checking over the news, I can honestly say that I see the market's point.

Sales increased 12% during the quarter, and earnings from continuing operations calculated out to 30 cents per share, a huge improvement over the loss observed in the comparable period. According to Earnings.com, Wall Street was only looking for a measly four pennies for the bottom line.

Continue reading Del Monte up big on Q1 data

Heinz wins analyst game in Q1, generates higher level of cash

H.J. Heinz Company (NYSE: HNZ), a food company that shares space at the supermarket with products from Kraft Foods, Inc. (NYSE: KFT), ConAgra (NYSE: CAG), and Campbell Soup (NYSE: CPB), issued first-quarter data on Thursday. Even though the effect of currency translations continues to put a cloud over the top-line performance, management did end up beating earnings expectations.

Net sales came in flat, and net income was 67 cents per share. Analysts were expecting 5 cents less, according to Earnings.com. Shareholders should be happy about that. When I covered Heinz's last quarter, I noted that expectations were essentially beat by a penny.

Continue reading Heinz wins analyst game in Q1, generates higher level of cash

Clorox increases prices -- and profit -- in Q4

The Clorox Company (NYSE: CLX), a famous supermarket brand similar to companies such as Procter & Gamble (NYSE: PG) and Colgate-Palmolive (NYSE: CL), reported Q4 earnings today. Excluding certain factors, Clorox increased its per-share profit by 18% to $1.35.

The dollar continues to wreak havoc on companies with international exposure (there's a whole lot of them, of course). Including currency translations, Clorox's top line was flat. Without the effect (and excluding the impact of a private-label business that the company exited), sales increased 3%. The company utilized price increases to help offset the tough times. Unfortunately, volume decreased 2% during the quarter.

Continue reading Clorox increases prices -- and profit -- in Q4

Kellogg's Q2 more nutritious than analysts thought

Kellogg (NYSE: K), the famous cereal concern that competes with General Mills (NYSE: GIS), distributed a box of Q2 earnings to the market yesterday. Were they as nutritious as one of the company's breakfast foods?

Everything turned out all right for shareholders. Sales weren't so hot: the top line decreased 3% on dollar pressures. Earnings per share saved the day, coming in at 92 cents, good for a 12% increase. The income amount also beat expectations by a very significant margin. Analysts wanted to see at least 83 cents for per-share profit, according to Earnings.com.

Continue reading Kellogg's Q2 more nutritious than analysts thought

Colgate-Palmolive beats estimates in Q2

Colgate-Palmolive (NYSE: CL), whose colleagues at the supermarket include companies like Procter & Gamble (NYSE: PG) and Clorox (NYSE: CLX), did all right in the second quarter. Sales were inhibited by currency rates: they dropped by well over 5%. The bottom line, on the other hand, fared a lot better. The company made $1.07 per share compared to 92 cents per share in the year-ago period. However, the previous year's quarter had 6 cents of charges to take into account, so the adjusted earnings in 2008 actually comes out to 98 cents. This makes the growth rate a modest 9%. The market was expecting $1.05 per share according to Earnings.com, so management beat by two pennies.

I was surprised a little by how the stock sold off on Thursday after the earnings report. Shares of Colgate-Palmolive closed down over 5% on very active volume.

Continue reading Colgate-Palmolive beats estimates in Q2

Johnson & Johnson (JNJ): A triple A play

"Johnson & Johnson (NYSE: JNJ) has vast holdings, but its strategy is simple: Support a deep pipeline of new drugs and medical devices with an aggressive acquisition strategy and cost controls," notes blue chip investor Richard Moroney.

In his Dow Theory Forecasts, he adds, "And despite the recession, J&J has kept its financial footing, remaining one of the few companies with the top credit rating of AAA." Here's his long term outlook.

"This year the U.S. pharmaceutical market is expected to contract for the first time in 50 years as fewer people visit doctors or start new therapies for chronic conditions.

"Beyond 2009, an economic recovery should reinvigorate J&J, though it is too early to determine whether health-care reform will help or harm the company.

Continue reading Johnson & Johnson (JNJ): A triple A play

Hershey destroys the analysts in Q2

The Hershey Company (NYSE: HSY) announced Q2 earnings on Thursday. Shareholders of the confection company should definitely appreciate the growth reported. Net sales increased almost 6%. On an adjusted basis, earnings per share went up a whopping 48% to 43 cents.

According to Earnings.com, analysts were expecting only 35 cents per share. Hershey's management went the extra distance on this one. Not only was the magnitude of the beat impressive, but as Reuters points out, Hershey raised its guidance for the full fiscal year, something that is obviously a positive signal to the marketplace.

Continue reading Hershey destroys the analysts in Q2

Kimberly-Clark up on Q2 numbers

Kimberly-Clark (NYSE: KMB), a consumer-products company that counts Procter & Gamble (NYSE: PG) and Colgate-Palmolive (NYSE: CL) as colleagues, announced Q2 results on Thursday. The performance wasn't spectacular, but management successfully defended the bottom line from the recession by instituting pricing strategies that leveraged the brand equity of the company's portfolio.

The bottom line fell, of course, but probably not as far as it would have if there weren't any pricing mechanisms in place. Earnings per share came in at 97 cents. This was six cents lower than last year's adjusted Q2 income. Revenues were challenged by dollar fluctuations, dropping well over 5%. However, here's the silver lining: organic sales increased almost 3%, even with volumes on the decline.

Continue reading Kimberly-Clark up on Q2 numbers

WD-40 beats earnings, aided by drop in oil price

Consumer-products concern WD-40 (NASDAQ: WDFC) had something of a rough third quarter. According to the press release, which was issued on Wednesday after the bell, sales were down over 16%. The company made 41 cents per diluted share. This was 8 cents less than the previous year's Q3 performance.

It was, however, 3 cents better than what the analysts were looking for, according to Earnings.com. Gross margin, it should also be noted, improved significantly. Driving this positive element of the story were efficiencies in the supply chain, price increases, and the drop in the price of oil.

Continue reading WD-40 beats earnings, aided by drop in oil price

Clorox's upgrade and new dividend level: Which is better?

The Clorox Company (NYSE: CLX), a company whose compatriots at the supermarket include Procter & Gamble (NYSE: PG) and Colgate-Palmolive (NYSE: CL), gave and received some good news this week. First, let's mention the giving. Management saw fit to increase the dividend that it pays to shareholders. The quarterly payout went up 9% to $0.50 per share.

Now, for the receiving. According to an earlier item on BloggingStocks, Oppenheimer thinks the stock is worthy of an outperform rating. A price target of $70 has been set. Which is impressive, since the price of Clorox as of this writing is $56.32 per share.

Continue reading Clorox's upgrade and new dividend level: Which is better?

Del Monte's Q4 rocked -- buy or sell on the news?

Shares of Del Monte (NYSE: DLM) are up over 9% in early afternoon trading. And the volume is doing gangbusters business. The market is responding to the company's fourth-quarter results. The numbers did tell an overall fun story.

To begin with, revenues saw a big jump of 20%. As many news items have pointed out, price increases helped out. It should also be pointed out that the company's press release indicated that an extra week skewed things a bit. That's okay, though, it was still a good top-line performance. Earnings per share from continuing divisions came in at $0.35, which meant that Del Monte grew the bottom line by 75% (a couple elements affecting the perception of this profit expansion was a better tax situation linked to a positive change in California tax code and a $0.04 per-share transformation expense recorded in Q4 2008). Analysts said the company might earn $0.26 per share. That's a pleasant difference, isn't it?

Continue reading Del Monte's Q4 rocked -- buy or sell on the news?

Can Disney license its way to a stock rebound?

I'm always looking for a catalyst that is going to take Disney (NYSE: DIS) to the next level. The stock hasn't been a great performer over time. Just today, the Mouse issued a press release detailing its latest merchandising plans.

Merchandising falls under the consumer products division. Now, one would expect that this segment would always be rocking considering the brand equity inherent in all of Disney's intellectual properties. Well, let's remind ourselves of how the segment did during the last earnings report. In the second quarter, operating income for consumer products dipped 24%. For the six-month period, operating income was down by 13%. Double-digit declines: nobody likes them. Management commentary about the division specifically stated that lower royalty revenue from merchandise helped to drive the performance. As can be seen, Disney needs some good ideas and strategies to return this segment to growth.

Continue reading Can Disney license its way to a stock rebound?

Next Page >

Symbol Lookup
IndexesChangePrice
DJIA+17.4610,023.42
NASDAQ+7.122,112.44
S&P 500+2.671,069.30

Last updated: November 08, 2009: 06:15 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance